Prospect Financial Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$244K Sell
1,709
-466
-21% -$70.7K 0.2% 54
2026
Q2
$341K Buy
2,175
+41
+2% +$6.15K 0.27% 50
2026
Q1
$326K Hold
2,134
– – 0.3% 44
2025
Q4
$294K Hold
2,134
– – 0.27% 46
2025
Q3
$274K Hold
2,134
– – 0.27% 48
2025
Q2
$258K Buy
2,134
+2
+0.1% +$225 0.27% 47
2025
Q1
$238K Buy
2,132
+5
+0.2% +$532 0.3% 51
2024
Q4
$207K Hold
2,127
– – 0.25% 51

Other funds holding NVS

Prospect Financial Group's NVS Position: Q3 2026 in Review

Prospect Financial Group reduced its Novartis (NVS) stake by 21% in Q3 2026, selling an estimated $70.7K and leaving 1,709 shares worth $244K. The position accounts for 0.2% of the portfolio, ranked #54.

Prospect Financial Group first reported a position in NVS in Q4 2024 and has held it in 8 quarters since. The position peaked at $341K in Q2 2026. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Prospect Financial Group held 1,709 shares of Novartis worth $244K as of Q3 2026.
  • Prospect Financial Group sold 466 Novartis shares in Q3 2026, an estimated $70.7K.
  • Novartis made up 0.2% of Prospect Financial Group's portfolio in Q3 2026, its #54 holding.
  • Prospect Financial Group first reported a position in Novartis in Q4 2024 and has held it in 8 quarters since.
  • Prospect Financial Group's Novartis position peaked at $341K in Q2 2026.
  • 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Prospect Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.